The debate over whether people ages 60 and up should take aspirin continues as medical experts learn more about the potential pros and cons of long-term use. Aspirin is an over-the-counter ...

In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) recurrence, according to a randomized study reported here. Patients with ...

Nearly one in three Americans over the age of 60 — roughly 19 million people — take aspirin daily, according to a 2021 study in Annals of Internal Medicine. Should you be among that group?

If you have ever had a heart attack, a healthcare provider has probably told you to carry an aspirin or two with you at all times to have available if you ever think you might be having another heart ...

A new survey found that 1 in 5 adults “who say they have no personal or family history of heart attack or stroke,” reported “routinely” taking a low-dose aspirin Kimberlee Speakman is a ...

If you're over the age of 60, you've likely seen headlines in the last couple of years warning against previous medical advice to take aspirin as a preventative measure against heart attack and ...

Nearly half of U.S. adults still believe that the benefits of taking low-dose aspirin daily outweighs the risks — despite new guidance that suggests otherwise, according to a new survey.

Expert Rev Cardiovasc Ther. 2012;10(4):433-439. This article suggests the need to reconsider the benefits of using aspirin in stroke prevention, especially in low-risk patients or patients not ...

5. In 1897, German chemist Felix Hoffman tried to concoct a less acidic formula to ease his father's arthritis. 6. The result, aspirin, was first marketed in Germany - it was the first drug sold ...

Many people still believe the benefits of taking an aspirin every day to prevent heart attacks and strokes outweigh the potential dangers – despite experts warning of the contrary more than five ...

In the study, "Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomized, double-blind, placebo-controlled trial ...